Program
TTYP01
A development code. Also written as “TTYP01 tables 60mg”, “TTYP01 tables 90mg” and “TTYP01 Tablets (12mg or 18mg)”.
Its studies are mostly in Alzheimer Disease · Autism Spectrum Disorder · Ischemic Stroke, led by Shanghai Auzone Biological Technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Auzone Biological Technology | 52 open or running | phase 3since Oct 15, 2024 | Apr 18, 2020 | Oct 23, 2028phase 2 · NCT07252440 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 18, 2020First study: phase 1 study in Healthy Adult SubjectsFirst studyNCT04370431 · 72 enrolled · Australia
- Oct 16, 2023Phase 1 study in Healthy Adult SubjectsNCT06107205 · 29 enrolled · United States
- Oct 15, 2024Phase 3 study in Ischemic StrokeNCT06648304 · 614 enrolled · China
- Dec 25, 2024Phase 2 study in Autism Spectrum DisorderNCT06757504 · 150 planned · China
- Nov 14, 2025Phase 2 study in Alzheimer DiseaseNCT07252440 · 180 planned · China
Ahead
- Oct 23, 2028Primary completion: phase 2 study in Alzheimer DiseaseNCT07252440
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07252440Alzheimer Disease · China | 2 | Recruiting | Oct 23, 2028 | 180 |
| NCT06757504Autism Spectrum Disorder · China | 2 | Recruiting | Feb 6, 2026 | 150 |
| NCT06648304Ischemic Stroke · China | 3 | Completed | Jun 17, 2024 | 614 |
| NCT06107205Healthy Adult Subjects · United States | 1 | Completed | Dec 14, 2023 | 29 |
| NCT04370431Healthy Adult Subjects · Australia | 1 | Completed | Dec 17, 2020 | 72 |
How it is read
Names in the registry
- “TTYP01 tables 60mg”, 1 entry
- “TTYP01 tables 90mg”, 1 entry
- “TTYP01”, 1 entry
- “TTYP01 Tablets (12mg or 18mg)”, 1 entry
- “TTYP01 tablets”, 1 entry
Codes read as this program: TTYP01.
Conditions, from the studies’ own filings
- Alzheimer Disease, 1 study
- Autism Spectrum Disorder, 1 study
- Ischemic Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.